Floatz logo

Trastuzumab Deruxtecan

Esophageal Adenocarcinoma

Boehringer Ingelheimantibody_drug_conjugatePhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

47 Active assets in the Esophageal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
I-Mab Biopharma US Limited
Phase 3BB
Capecitabine
I-Mab Biopharma US Limited
Phase 3B
Cetuximab
BeOne Medicines
Phase 2B
Tislelizumab
BeOne Medicines
Phase 3B
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3B

View all 50 →

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

HER2-low Expressing Breast CancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →